lisinopril / Generic mfg. - LARVOL DELTA

SUCCESSFUL PARENT-TO-CHILD LIVING KIDNEY DONATIONS WITHIN FAMILY MEMBERS AFFECTED WITH COENZYME Q8B NEPHROPATHY: TWO CASE SERIES (ISN-WCN 2026) - "The addition of lisinopril was not beneficial, and the patient progressed to ESKD...Two years after the KTx, kidney function and urinalysis results were within normal levels in both the recipient and donor without post-transplant disease recurrence.Conclusion Although kidney donation from biologically related donors is generally associated with a higher risk of allograft failure in recipients and future kidney dysfunction in donors, living KTx from the parents as heterozygotes of COQ8B mutation to the COQ8B nephropathy siblings was uneventfully performed without post-transplant recurrence in the recipients or kidney dysfunction in the donors. Parent-to-child KTx may be an effective treatment option within family members affected with COQ8B nephropathy.This work was first presented at Western Regional Meeting of JSN 2025, and re-submission is permitted by JSN"

Clinical • Anorexia • Focal Segmental Glomerulosclerosis • Genetic Disorders • Glomerulonephritis • Nephrology • Renal Disease • B2M

A HIDDEN HAZARD OF HEPARIN: LIFE-THREATENING HYPONATREMIA AND HYPERKALEMIA DUE TO TYPE IV RTA (ISN-WCN 2026) - "He subsequently received unfractionated heparin for thromboprophylaxis and dexamethasone for cord compression...Hypertonic saline, sodium zirconium cyclosilicate, and fludrocortisone were administered, and heparin, lisinopril, and hydrochlorothiazide were discontinued, resulting in rapid normalization of serum sodium, potassium, bicarbonate, and blood pressure.Results Download: Download high-res image (159KB)Download: Download full-size imageConclusion Although heparin associated Type 4 RTA is a well-known pharmacologic effect, its clinical impact is often underestimated...This case highlights that even routine heparin prophylaxis can cause severe aldosterone deficiency. Prompt recognition and discontinuation of heparin, along with temporary mineralocorticoid replacement, can be lifesaving."

Cardiovascular • Cognitive Disorders • Endocrine Disorders • Genito-urinary Cancer • Heart Failure • Hypertension • Metabolic Disorders • Nephrology • Prostate Cancer • Renal Disease • Solid Tumor

Angiotensin-Converting Enzyme (ACE) Inhibitor-Associated Hypersensitivity Vasculitis With Small Bowel Edema: A Case Report. (PubMed, Cureus) - "Lisinopril was initiated at the time of admission and continued throughout the perioperative period; symptoms occurred approximately three weeks after treatment initiation, with no prior history of similar episodes...This case highlights that ACE inhibitor-associated hypersensitivity vasculitis may present with small bowel edema and imaging findings overlapping with intestinal angioedema. Careful medication review and recognition of associated systemic features such as purpura and eosinophilia are essential to avoid unnecessary invasive procedures."

Journal • Cardiovascular • Eosinophilia • Gastrointestinal Disorder • Immunology • Pain • Vasculitis

CLM-HTN-006: OptiZ: Real World Evidence Study (clinicaltrials.gov) - P=N/A | N=0 | Withdrawn | Sponsor: Closed Loop Medicine | N=113 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • HEOR • Real-world evidence • Trial withdrawal • Cardiovascular • Hypertension

Temporal Risk of Non-Melanoma Skin Cancer with Lisinopril and Hydrochlorothiazide as Monotherapy and in Combination: A Retrospective Cohort Study Using the TriNetX Database (AAD 2026) - "Z-scores between cohorts identified HCTZ alone to carry a significantly greater risk of cSCC at 5 years [RR=3.01 (2.15, 4.213), p<0.0001] when compared to combination LIS+HCTZ. Our study demonstrates that LIS and HCTZ either taken in combination or as monotherapy for HTN increases the risk of NMSC development."

Monotherapy • Retrospective data • Basal Cell Carcinoma • Genetic Disorders • Hypertension • Non-melanoma Skin Cancer • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Skin Cancer

DILATED BY A DRINK: A CASE OF PPA2-RELATED CARDIOMYOPATHY (ACC 2026) - "Guideline-directed medical therapy (enalapril, spironolactone, metoprolol) was initiated for reverse remodeling, as well as a mitochondrial cocktail (CoQ10, levocarnitine, vitamin B complex) to optimize mitochondrial function. Lisinopril was avoided due to mannitol excipient... PPA2 deficiency is a rare presentation of cardiomyopathy in adolescents which can be precipitated by alcohol consumption and can be fatal if not promptly identified. Management requires multidisciplinary care including cardiology, neurology, and metabolism."

Clinical • Cardiomyopathy • Cardiovascular • Infectious Disease • Inflammation • Metabolic Disorders

HYPERTENSION-INDUCED ATYPICAL APICAL HYPERTROPHIC CARDIOMYOPATHY WITH PHENOTYPIC REGRESSION FOLLOWING TREATMENT (ACC 2026) - "Given bradycardia and no obstructive features, hypertension was treated with lisinopril... This case demonstrates resolution of atypical ApHCM after treating hypertension, implying hypertension may trigger phenotypic expression. The patient's course highlights the possibility of incomplete genetic penetrance of HCM, the role of CMR in characterizing subtle ApHCM morphologies, and the benefit of tailored approach of management."

Cardiomyopathy • Cardiovascular • Hypertension • Hypertrophic Cardiomyopathy

APICAL VARIANT HYPERTROPHIC CARDIOMYOPATHY IN A TRANSPLANTED HEART (ACC 2026) - "Case: A 69-year-old female with a past medical history of well controlled hypertension on lisinopril, and non-ischemic cardiomyopathy from viral myocarditis, received a heart transplant 22 years ago, maintained on tacrolimus and prednisone for immunosuppression. Her post-transplant course was complicated by new onset diabetes, severe tricuspid regurgitation, cyclosporine induced seizures and recurrent squamous cell carcinoma of the skin... Apical HCM is rarely reported in transplanted hearts. When considering the etiology of HCM the most common cause is rejection, an idiopathic genetic variant for which the donor would be susceptible and some forms of chronic immunosuppression such as calcineurin inhibitors. In this patient's case her cause of apical HCM is unclear, but likely multifactorial in the setting of chronic hypertension and immunosuppression."

Atrial Fibrillation • Cardiomyopathy • Cardiovascular • CNS Disorders • Diabetes • Epilepsy • Hypertension • Hypertrophic Cardiomyopathy • Metabolic Disorders • Non-melanoma Skin Cancer • Squamous Cell Carcinoma • Squamous Cell Skin Cancer • Transplantation

A RARE CORONARY TRIFECTA: UNIQUE INTERSECTION OF MYOCARDIAL BRIDGING, SPONTANEOUS CORONARY ARTERY DISSECTION AND TAKOTSUBO CARDIOMYOPATHY (ACC 2026) - "Decision-Making: She was managed with lisinopril, metoprolol, and six months of dual antiplatelet therapy... Recognition of these associations is essential, as management requires individualized strategies. Further study is needed to define optimal therapy."

Cardiomyopathy • Cardiovascular • Coronary Artery Disease

Bimekizumab in Pityriasis Rubra Pilaris: an Innovative Therapeutic Option (AAD 2026) - "We present an 81-year-old male patient with a past medical history of hypertension and arrythmias, on lisinopril and metoprolol tartrate, with no recent lifestyle or medication changes who presented with a diffuse rash. No clear pathogenesis has been established for PRP, outside of inherited mutations of CARD14. This case demonstrates the efficacy and utility of bimekizumab as a treatment option in PRP refractory to classic therapeutic options."

Ankylosing Spondylitis • Cardiovascular • Hidradenitis Suppurativa • Hypertension • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Seronegative Spondyloarthropathies • Spondylarthritis

Ten Years Ago, I Would've Called This... (USCAP 2026) - "The patient's current medication list includes lisinopril for her hypertension and lipoic acid for her neuropathy/parasethesia...BMI is normal. Figure 1: Click to view full size Figure 1 Caption: H&E 50x Figure 2: Click to view full size Figure 2 Caption: H&E 100x Figure 3: Click to view full size Figure 3 Caption: PAS 400x Figure 4: Click to view full size Figure 4 Caption: Jones 400x Figure 5: Click to view full size Figure 5 Caption: Jones 600x Figure 6: Click to view full size Figure 6 Caption: Immunofluorescence, 200x Figure 7: Click to view full size Figure 7 Caption: Immunofluorescence, 200x Figure 8: Click to view full size Figure 8 Caption: Immunofluorescence, 200x Figure 9: Click to view full size Figure 9 Caption: Immunofluorescence, 200x Figure 10: Click to view full size Figure 10 Caption: Immunofluorescence, 200x Figure 11: Click to view full size Figure 11 Caption: Electron microscopy, 4000x Figure12: Click to view full size Figure 12 Caption:..."

Brain Cancer • Cardiovascular • Hypertension • Meningioma • Renal Disease • Solid Tumor

Molecular Lung Imaging Following Exposure to Radiation Predicts Long-Term Survival in Rats. (PubMed, Int J Mol Sci) - "Early dual-tracer molecular lung imaging predicted long-term survival after radiation exposure and tracked mitigation with lisinopril. Circulating mtDAMPs may provide complementary systemic information to further strengthen early risk stratification after radiation exposure."

Biomarker • Journal • Preclinical • Inflammation • Pneumonia • Respiratory Diseases

A Diagnostic Pitfall: Carbamazepine-Induced Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome Masquerading As Angiotensin-Converting Enzyme Inhibitor Angioedema. (PubMed, Cureus) - "Approximately seven weeks later, he presented with a generalized rash, angioedema, and mucosal swelling, initially attributed to his concurrent lisinopril therapy. This case underscores the critical importance of considering DRESS in any patient with a rash and systemic symptoms occurring two to eight weeks after initiation of a high-risk drug, even in the presence of other potential culprits. It highlights that clinical progression despite withdrawal of one suspected agent should prompt urgent re-evaluation for an alternative etiology, such as DRESS."

Journal • Allergy • Cardiovascular • Chronic Kidney Disease • Eosinophilia • Hypertension • Immunology • Nephrology • Neuralgia • Pain • Renal Disease

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P3 | N=10000 | Recruiting | Sponsor: UMC Utrecht | Phase classification: P4 ➔ P3 | N=7100 ➔ 10000 | Trial completion date: Dec 2023 ➔ Dec 2025 | Trial primary completion date: Dec 2021 ➔ Dec 2023

Enrollment change • Phase classification • Trial completion date • Trial primary completion date • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P4 | N=6800 | Recruiting | Sponsor: MJM Bonten | N=4000 ➔ 6800 | Trial completion date: Feb 2019 ➔ Jun 2022 | Trial primary completion date: Feb 2019 ➔ Dec 2021 | Initiation date: Dec 2015 ➔ Apr 2016

Enrollment change • Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P4 | N=7100 | Recruiting | Sponsor: MJM Bonten | Trial completion date: Jun 2022 ➔ Dec 2023

Trial completion date • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P4 | N=4000 | Recruiting | Sponsor: UMC Utrecht

New P4 trial • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P3 | N=10000 | Recruiting | Sponsor: UMC Utrecht | Trial completion date: Dec 2025 ➔ Feb 2028 | Trial primary completion date: Dec 2023 ➔ Feb 2026

Trial completion date • Trial primary completion date • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P3 | N=20000 | Recruiting | Sponsor: UMC Utrecht | N=10000 ➔ 20000

Enrollment change • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

AIFA-CARDIO-129: Pharmacological optimization in prevention in Heart Failure: A Sex-gap? (clinicaltrialsregister.eu) - P4 | N=368 | Not yet recruiting | Sponsor: Policlinico San Donato S.p.A.

New P4 trial • Cardiovascular • Congestive Heart Failure • Heart Failure

Illness and Health Outcomes of Atypical Hemolytic Uremic Syndrome Not Treated with Long Term C5 Inhibitor Therapy: A Case Study (NKF-SCM 2026) - "RESULTS/CASE DISCUSSION The patient remained relapse-free six months after his last infusion with only two upper respiratory illnesses and a hypotensive episode thought to be related to lisinopril and/or meningitis vaccination. This case demonstrates Eculizumab may be discontinued after short treatment if patients with CD46-associated aHUS achieve remission. CONCLUSION Although Eculizumab helps maintain aHUS remission, there are reasons to discontinue treatment in stable patients such as infection risk, decreased quality of life, and treatment cost.2 Further research is needed to create conservative, evidence-based guidelines on Eculizumab courses for aHUS."

Case study • Clinical • HEOR • Acute Kidney Injury • Atypical Hemolytic Uremic Syndrome • Cardiovascular • CNS Disorders • Complement-mediated Rare Disorders • Gastrointestinal Disorder • Hematological Disorders • Hypertension • Infectious Disease • Nephrology • Rare Diseases • Renal Disease • Respiratory Diseases • Thrombocytopenia • CD46

Pediatric Complement 3 Glomerulonephritis (C3GN) Responsive to Mycophenolate mofetil (NKF-SCM 2026) - "Prednisone (2 mg/Kg/day) and Lisinopril were started at 1.5 months...As UPCR remains elevated (~4.09 mg/mg), empagliflozin was added...RESULTS/CASE DISCUSSION Despite the availability of Pegcetacoplan or Iptacopan, these are not currently approved for children under 12 years of age. Complement inhibitors including Eculizumab/ Ravuluzimab will carry potential life threatening risk of infections. CONCLUSION This case highlights MMF as a viable long-term management strategy in refractory C3GN in young patients intolerant or resistant to corticosteroids."

Clinical • Glomerulonephritis • Infectious Disease • Lupus Nephritis • Nephrology • Pediatrics • Renal Disease

Z-2025058: A trial investigating partial withdrawal of heart failure therapy in patients with heart failure in remission. (clinicaltrialsregister.eu) - P4 | N=100 | Not yet recruiting | Sponsor: Ziekenhuis Oost Limburg

New P4 trial • Cardiovascular • Congestive Heart Failure • Heart Failure

Methyl Palmitate, a potent Angiotensin Converting Enzyme inhibitor attenuates vascular remodelling in L-NG-Nitro Arginine Methyl Ester-induced hypertensive Wistar rat models. (PubMed, J Vasc Res) - "MP demonstrates strong natural ACE inhibition, antioxidant, and vascular protective effects, supporting further research for therapeutic optimization."

Journal • Preclinical

Reversing the irreversible? A case of successful surgical repair in a late-presenting aortopulmonary window with severe pulmonary hypertension. (PubMed, Egypt Heart J) - "This case suggests that operability in APW may not be irrevocably lost beyond infancy in carefully selected adolescents. It underscores the importance of individualized assessment, medical preconditioning and serial haemodynamic reassessment to unmask latent pulmonary vasoreactivity. Larger series are needed to define which late-presenting patients with APW and PH may safely benefit from definitive surgical repair."

Journal • Cardiovascular • Heart Failure • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases